Department of Defense Anthrax Vaccine Immunization Program: Hearings Before the Committee on Armed Services, United States Senate, One Hundred Sixth Congress, Second Session, April 13 and July 12, 2000, Volumen4
U.S. Government Printing Office, 2001 - 244 páginas
Comentarios de la gente - Escribir un comentario
No encontramos ningún comentario en los lugares habituales.
Otras ediciones - Ver todas
additional Administration adverse events agent animal anthrax vaccine approved areas Army assessed biological warfare BioPort BLANCK cause Chairman WARNER civilian Committee concerns conducted CONGRESS continue contract correct Department of Defense determine discussed disease doses Drug effective efficacy evaluated Expert facility forces given going hearing human immunization individuals inhalation initial inspection issue LIBRARY license look lots manufacturing meet Michigan military million months occur Office OLIVER percent personnel Phase possible potential problems production protection question reactions received recommended record release reports response safe safety schedule Secretary DE LEON Senator Senator ALLARD service members statement stockpile strains submitted supply symptoms testing Thank threat tion United VAERS weapons West Zoon
Página 235 - Health screening programs are popular, the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC...
Página 32 - Identifying potential problems, the reports on anthrax vaccine received thus far do not raise any specific- concerns about -the safety of the vaccine. As more people receive the vaccine, the numbers of adverse events reported will increase. .FDA continues to view the anthrax vaccine as safe and effective for individuals at risk of exposure to anthrax. LOT RELEASE As mentioned above, because of the complex manufacturing processes for most biological products, each product lot undergoes thorough testing...
Página 101 - The available studies are of insufficient quality, consistency or statistical power to permit a conclusion regarding the presence or absence of a causal association, or no data on cancer in humans are available.
Página 30 - Standards issued a product license to MDPH to manufacture anthrax vaccine. Approved labeling for the anthrax vaccine states that immunization with this product is recommended for individuals who may come in contact with animal products that may be contaminated with Bacillus anthracis spores; and for individuals engaged in diagnostic or investigational activities which may bring them in contact with Bacillus anthracis spores. It is also recommended for persons at high risk, such as veterinarians and...
Página 60 - Anthrax is an infectious disease caused by the bacterium Bacillus anthracis and is spread by contact with infected animals, handling infected products, eating infected meat, or inhaling weapon-dispersed anthrax spores. Of all known biological warfare agents, anthrax spores are the top choice in biological weapons for "germ warfare.
Página 102 - The committee's findings are best regarded as an early step in the complex process of understanding the vaccine's safety, which began with the vaccine's licensure in 1970 and the 1985 FDA advisory pane!
Página 29 - ... vaccine lot and the results if their own tests for potency, safety, and sterility to the Agency before release of each lot of the licensed product, because of the complex manufacturing processes for most biological products. In addition, licensed establishments are inspected regularly by FDA. Let us now turn to anthrax.
Página 59 - Blagojevich and Distinguished Committee Members, I am honored to appear before your Committee today to address your questions regarding the Anthrax Vaccine Immunization Program (AVIP).
Página 32 - DOD requested: that. :CDC,:: in: conjunction with the Health Resources and Services Administration, National Vaccine Injury Compensation Program (VICP) , organize and coordinate a program to evaluate VAERS reports for the anthrax vaccine - In response- to the request by DoD, a group of non-government medical experts was convened by .the VICP in the fall of 1998 as the Anthrax Vaccine Expert Committee (AVEC) . AVEC, coordinated by VICP, has met eight times since 1998. These experts have been reviewing'...